
OCUP
Healthcare · Biotechnology · $31.7M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · -8.7% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2024 | Before the open | -0.25 | -0.30 | -20.0% |
| May 10, 2024 | Before the open | -0.13 | -0.29 | -123.1% |
| Mar 8, 2024 | Before the open | -0.05 | -0.21 | -320.0% |
| Nov 13, 2023 | Before the open | -0.22 | 0.25 | +213.6% |
| Aug 11, 2023 | Before the open | -0.23 | -0.24 | -4.3% |
| May 15, 2023 | Before the open | -0.15 | -0.28 | -86.7% |
| Mar 30, 2023 | Before the open | 0.97 | 1.58 | +62.9% |
| Nov 4, 2022 | After the close | -0.29 | -0.22 | +24.1% |
| Aug 12, 2022 | Before the open | -0.33 | -0.25 | +24.2% |
| May 13, 2022 | Before the open | -0.35 | -0.35 | 0.0% |
| Mar 24, 2022 | Before the open | -0.29 | -0.35 | -20.7% |
| Nov 12, 2021 | Before the open | -0.36 | -0.25 | +30.6% |
| Aug 12, 2021 | Before the open | -0.36 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal…
| -0.52 |
| -44.4% |
| May 7, 2021 | Before the open | -0.71 | -0.47 | +33.8% |
| Mar 10, 2021 | After the close | -0.42 | -5.18 | -1133.3% |
| Oct 29, 2020 | After the close | -0.33 | -0.33 | 0.0% |
| Aug 14, 2020 | After the close | -0.62 | -0.62 | 0.0% |
| May 7, 2020 | After the close | -0.15 | -0.15 | 0.0% |
| Feb 21, 2020 | After the close | -0.50 | -1.86 | -272.0% |
| Nov 6, 2019 | After the close | -2.16 | -1.96 | +9.3% |
| Aug 7, 2019 | Before the open | -3.41 | -2.44 | +28.4% |
| May 10, 2019 | After the close | -3.73 | -2.48 | +33.5% |
| Mar 7, 2019 | After the close | -6.24 | -4.32 | +30.8% |
| Nov 2, 2018 | After the close | -8.16 | -8.16 | 0.0% |
| Aug 3, 2018 | After the close | -8.76 | -5.76 | +34.2% |
| May 4, 2018 | After the close | -6.72 | -3.36 | +50.0% |
| Mar 9, 2018 | After the close | -6.56 | -4.32 | +34.1% |